Genprex (GNPX) Appoints Jose A. Moreno Toscano as Board Chair

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner.

Prior to his appointment as Chairman, Mr. Moreno Toscano has served on Genprex's Board of Directors since March 2020. Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc, the US subsidiary of LFB Group, a global integrated biopharmaceutical company, and he has more than 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations and general management.

Mr. Moreno Toscano's appointment follows the recent appointment of Ryan Confer to serve as Genprex's President and Chief Executive Officer. Mr. Confer was also appointed to Genprex's Board of Directors.

Mr. Moreno Toscano commented:

"On behalf of Genprex's Board of Directors, we wish to express our support for Ryan as Genprex's new President and Chief Executive Officer. We have worked closely with Ryan over the last several years, and we have seen his robust leadership skills and exceptional operational organization. He has strengthened the company's operational and financial foundation, bolstered the company's talent and culture, added value in every company department and has continuously advanced the company's strategies year after year. I look forward to working alongside Ryan and our other fellow directors in my role as Chairman in what I believe will be a transformational time for Genprex."

You May Also Be Interested In

• Rocket Companies adds Sarah Watterson to its board of directors
• Ainos launches second-generation AI Nose for industrial deployment
• Nano Dimension names Nadav Kidron to board, to chair new committee